Tegafur,Gimeracil and Oteracil Potassium

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of

and more 60 locations

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Phase 3

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: KC1036
Drug: Irinotecan
Drug: Docetaxel
Drug: S-1

First Posted Date: 2024-01-08

Last Posted Date: 2024-03-07

Lead Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.

Target Recruit Count: 490

Registration Number: NCT06194734

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

Phase 2

Recruiting

Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions: Drug: S-1
Drug: Toripalimab
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2024-01-02

Last Posted Date: 2024-03-12

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 140

Registration Number: NCT06187597

Locations: 🇨🇳
Mian Xi, Guangzhou, Guangdong, China

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Previously AG Chemotherapy Treated Pancreatic Cancer

Interventions: Drug: Zimberelimab
Drug: Oxaliplatin
Drug: S-1
Drug: Irinotecan

First Posted Date: 2023-12-12

Last Posted Date: 2023-12-12

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 19

Registration Number: NCT06166589

Locations: 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumor
Non-small Cell Lung Cancer
Gastric Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: RO7496353
Drug: Capecitabine
Drug: Atezolizumab
Drug: Nab-paclitaxel
Drug: S-1
Drug: Gemcitabine
Drug: Nivolumab
Drug: Oxaliplatin

First Posted Date: 2023-05-19

Last Posted Date: 2024-12-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 102

Registration Number: NCT05867121

Locations: 🇺🇸
UCLA University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

and more 26 locations

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: AK104
Drug: Apatinib
Drug: Paclitaxel
Drug: S-1

First Posted Date: 2023-05-10

Last Posted Date: 2023-05-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05853172

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Immunotherapy Gastrict Cancer

Interventions: Drug: Tislelizumab
Drug: apatinib
Drug: oxaliplatin
Drug: S-1

First Posted Date: 2023-01-26

Last Posted Date: 2024-05-01

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 130

Registration Number: NCT05699655

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Phase 2

Recruiting

Conditions: Gastric Cancer
Gastroesophageal-junction Cancer

Interventions: Drug: Tislelizumab
Drug: S-1
Drug: Nab paclitaxel
Drug: Oxaliplatin
Radiation: Radiation

First Posted Date: 2023-01-18

Last Posted Date: 2023-04-19

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 140

Registration Number: NCT05687357

Locations: 🇨🇳
Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China
🇨🇳
Wuhan Tongji Hospital, Wuhan, Hubei, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: S-1
Procedure: Intraperitoneal chemotherapy with paclitaxel

First Posted Date: 2022-11-25

Last Posted Date: 2022-11-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05627414

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy